UT Southwestern study suggests new treatment target for deadly brain tumors
A study by UT Southwestern Medical Center researchers published online in Nature reveals new insight into why the most common, deadly kind of brain tumor in adults recurs and identifies a potential target for future therapies. Using a genetically engineered mouse model of glioblastoma multiforme (GBM), the researchers identified a subset of brain tumor cells that appear to be the source of cancer recurrence after therapy with the drug temozolomide. The UT Southwestern Medical Center is home to the Harold C. Simmons Cancer Center.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.